Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

FDA Approves Tremelimumab in Combination With Durvalumab For Unresectable Hepatocellular Carcinoma

Oncology Practice Insider

Related

FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection in Patients with Hematologic Malignancies
FDA Approves Dabrafenib With Trametinib For Pediatric Patients With Low-grade Glioma With a BRAF V600E Mutation
FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy
FDA Alerts

On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Read more.